医学
内科学
不良事件通用术语标准
中性粒细胞减少症
发热性中性粒细胞减少症
胃肠病学
不利影响
实体瘤疗效评价标准
耐火材料(行星科学)
肺癌
癌症
化疗
肿瘤科
临床研究阶段
天体生物学
物理
作者
Tomonori Araki,Atsuo Takashima,Tetsuya Hamaguchi,Yoshitaka Honma,Satoru Iwasa,Natsuko Okita,K. Kato,Yasuhide Yamada,H. Hashimoto,Hirokazu Taniguchi,Ryoji Kushima,Kazuwa Nakao,Narikazu Boku,Yasuhiro Shimada
出处
期刊:Anti-Cancer Drugs
[Ovid Technologies (Wolters Kluwer)]
日期:2016-09-01
卷期号:27 (8): 794-799
被引量:13
标识
DOI:10.1097/cad.0000000000000393
摘要
Although the same treatment strategy as used for small cell lung cancer, including second-line chemotherapy, is generally applied to metastatic neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) of the gastrointestinal tract (GIT; GIT-NEC/MANEC), the efficacy of amrubicin (AMR) for GIT-NEC/MANEC is not well known. We retrospectively analyzed platinum-refractory GIT-NEC/MANEC patients who received AMR between February 2004 and July 2012 at the National Cancer Center Hospital. The AMR dose administered was 30–45 mg/m2 on days 1–3 every 3–4 weeks. The overall response rate according to Response Evaluation Criteria in Solid Tumors guidelines, version 1.0, progression-free survival, overall survival, and adverse events by National Cancer Institute-Common Terminology Criteria for Adverse Events guidelines, version 4.0 were evaluated. Nineteen patients received AMR. The response rate for 16 assessable patients was 18.8% (95% confidence interval, 4.1–45.7), the median progression-free survival was 3.8 months (2.3–5.3), and the median overall survival was 7.7 months (7.1–8.2). Grade 3/4 neutropenia occurred in 52.6% of patients and febrile neutropenia occurred in 10.5%. Other nonhematological toxicities were mild and treatment-related deaths were not observed. AMR may have a modest effect, with tolerable toxicities, on patients with platinum-refractory GIT-NEC/MANEC. Further prospective evaluations are warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI